全文获取类型
收费全文 | 5779篇 |
免费 | 343篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 127篇 |
妇产科学 | 128篇 |
基础医学 | 1094篇 |
口腔科学 | 154篇 |
临床医学 | 606篇 |
内科学 | 945篇 |
皮肤病学 | 155篇 |
神经病学 | 738篇 |
特种医学 | 339篇 |
外科学 | 618篇 |
综合类 | 30篇 |
一般理论 | 2篇 |
预防医学 | 304篇 |
眼科学 | 114篇 |
药学 | 388篇 |
中国医学 | 5篇 |
肿瘤学 | 345篇 |
出版年
2023年 | 40篇 |
2022年 | 62篇 |
2021年 | 108篇 |
2020年 | 91篇 |
2019年 | 122篇 |
2018年 | 108篇 |
2017年 | 88篇 |
2016年 | 131篇 |
2015年 | 145篇 |
2014年 | 199篇 |
2013年 | 201篇 |
2012年 | 373篇 |
2011年 | 389篇 |
2010年 | 237篇 |
2009年 | 239篇 |
2008年 | 382篇 |
2007年 | 348篇 |
2006年 | 338篇 |
2005年 | 310篇 |
2004年 | 341篇 |
2003年 | 289篇 |
2002年 | 271篇 |
2001年 | 70篇 |
2000年 | 66篇 |
1999年 | 66篇 |
1998年 | 57篇 |
1997年 | 48篇 |
1996年 | 34篇 |
1995年 | 25篇 |
1994年 | 34篇 |
1993年 | 25篇 |
1992年 | 33篇 |
1991年 | 35篇 |
1990年 | 33篇 |
1989年 | 32篇 |
1986年 | 30篇 |
1985年 | 27篇 |
1983年 | 26篇 |
1982年 | 27篇 |
1980年 | 28篇 |
1979年 | 25篇 |
1977年 | 26篇 |
1976年 | 29篇 |
1975年 | 27篇 |
1938年 | 23篇 |
1935年 | 26篇 |
1926年 | 26篇 |
1925年 | 25篇 |
1924年 | 26篇 |
1923年 | 24篇 |
排序方式: 共有6140条查询结果,搜索用时 15 毫秒
1.
We have shown previously that the plant cannabinoid cannabidiol (CBD) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. Here, we investigated whether the main psychotropic constituent of cannabis, Δ9-tetrahydrocannabinol (THC) alone or in combination with other cannabis constituents can cause similar responses, and whether THC affects the responses induced by CBD. Our experiments were performed with 1 μM pure THC (pTHC), with 1 μM pure CBD (pCBD), with a high-THC, low CBD cannabis extract (eTHC), with a high-CBD, low THC cannabis extract (eCBD), with a mixture of eTHC and eCBD (THC:CBD = 1:1) or with corresponding ‘mock extracts’ that contained only pTHC and pCBD mixed in the same proportion as in eTHC, eCBD or the 1:1 mixture of eTHC and eCBD. 相似文献
2.
Prof. Dr. Alexander Kapp Prof. Dr. Bettina Wedi 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(10):854-854
Ohne Zusammenfassung 相似文献
3.
4.
J L Schrader 《The American journal of psychiatry》1987,144(1):107-109
The Alaska mental health program is endowed with a 1-million-acre trust fund. A coalition of groups that make up the mental health constituency of the state united in a lawsuit to establish the trust. The history of this legacy, the struggle to realize its benefits, its current status, and some of its psychopolitical significance are discussed. 相似文献
5.
6.
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
下载免费PDF全文
![点击此处可从《Neuropsychiatric Disease and Treatment》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change −42.5% vs +1.4% with placebo) and total seizures (−32.1% vs −11.7% with placebo), accompanied by significantly higher responder rates. These results are comparable with findings reported for other AEDs in randomized, controlled clinical trials in patients with LGS. Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability. The most frequently reported adverse events from a pooled safety database evaluating short- and long-term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue (13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile and is a promising candidate for the adjunctive therapy of LGS. 相似文献
7.
Klaus Rauber Kathrin S. Heidinger Bettina Kemkes-Matthes 《Cardiovascular and interventional radiology》1997,20(3):169-173
Purpose To determine the systemic effects of local fibrinolytic therapy with low-dose recombinant tissue-type plasminogen activator
(rt-PA).
Methods Ten patients received intrathrombal infusion of 20 mg rt-PA and heparin for local thrombolysis and had subsequent percutaneous
transluminal angioplasty (PTA). Eight controls underwent PTA and received heparin alone. We measured t-PA, D-Dimer, and fibrinogen
levels before, directly after, and 20, 40, and 60 min and 24 hr after therapy.
Results In the thrombolysis group the t-PA level peaked immediately after infusion and then declined within 1 hr. D-Dimer increased
and remained elevated, whereas in the control group only t-PA levels increased, and only after 24 hr. Fibrinogen remained
within the normal range in both groups. Eight of ten patients in the thrombolysis group and seven of eight with PTA had clinical
improvement after the procedure.
Conclusions The increase in D-Dimer in the rt-PA group indicates a good local fibrinolytic effect. The fact that fibrinogen levels remained
unchanged indicates that there is a lack of systemic fibrinogenolysis. 相似文献
8.
Monitoring left ventricular dilation in mice with PET. 总被引:3,自引:0,他引:3
Lars Stegger Klaus P Sch?fers Ulrich Fl?gel Lefteris Livieratos Sven Hermann Christoph Jacoby Petra Keul Edward M Conway Otmar Schober Jürgen Schrader Bodo Levkau Michael Sch?fers 《Journal of nuclear medicine》2005,46(9):1516-1521
Molecular imaging by small-animal PET is an important noninvasive means to phenotype transgenic mouse models in vivo. When investigating pathologies of the left ventricular (LV) myocardium, the serial assessment of LV volumes is important. By this, the presence of LV dilation as a sign of developing heart failure can be detected. Whereas PET is usually used to derive biochemical and molecular information, functional parameters such as ventricular volumes are generally measured using echocardiography or MRI. In this study, a novel method to monitor LV dilation in mice with PET is presented and evaluated using cardiac MRI. METHODS: A semiautomatic 3-dimensional algorithm was used to delineate the LV myocardial wall on static PET images depicting myocardial glucose metabolism ((18)F-FDG PET) for 20 mice: 10 wild-type and 10 genetically modified littermates designed to develop a dilative cardiomyopathy phenotype (cardiomyocyte-specific knockout of survivin). The volume enclosed by the 3-dimensional midmyocardial contour was calculated as a measure for LV volume for each mouse. Data were compared with ventricular volumes measured by MRI in the same animals. RESULTS: LV volumes obtained by PET and MRI correlated well (R = 0.89) for hearts with small and large left ventricles. In accordance with the hypothesis, the LV volumes were increased significantly for transgenic mice examined at an older age compared with those examined at a younger age (MRI: 160.5 +/- 25.7 microL vs. 114.7 +/- 15.2 microL [P = 0.012]; PET: 129.3 +/- 15.3 microL vs. 73.8 +/- 15.0 microL [P < 0.001], all values shown as mean +/- SD; for MRI, mean of end-diastolic and end-systolic volumes are given), whereas they did not for their wild-type littermates (MRI: 106.2 +/- 12.3 microL vs. 94.7 +/- 14.6 microL [P = 0.214]; PET: 82.6 +/- 20.9 microL vs. 65.0 +/- 16.9 microL [P = 0.185]). CONCLUSION: Evaluation and quantitation of LV dilation in both control and cardiomyopathic mice can be reliably and serially performed using small-animal PET and (18)F-FDG, yielding useful functional information in addition to metabolic data. 相似文献
9.
10.
Bettina Seiberlich Nicolas Hunzelmann Axel Roers Manfred Weber Eckhard Schulze-Lohoff 《Medizinische Klinik》2005,108(4):137-142
Namensgebend für das Jo-1-Syndrom sind Autoantikörper gegen das Jo-1-Antigen, die bei diesem Krankheitsbild im Serum der betroffenen Patienten nachgewiesen werden. Der Name Jo-1 leitet sich von dem ersten Patienten (John P.) ab, bei dem diese Antikörper gefunden wurden. Dieser Patient litt an einer Polymyositis und fibrosierenden Alveolitis. Das Jo-1-Antigen ist identisch mit der Histidyl-Transfer-RNA-Synthetase im Zytosol. Das Jo-1-Syndrom gehört zu einer Familie von Autoimmunerkrankungen, die als Anti-Synthetase- Syndrome bezeichnet werden. Diese Syndrome haben gemeinsam, dass jeweils Autoantikörper gegen unterschiedliche Aminosäure-Transfer-RNASynthetasen nachweisbar sind. Klinisch handelt es sich beim Jo-1-Syndrom um eine Sonderform der Poly- bzw. Dermatomyositis von bisher ungeklärter Ätiologie. Neben einer Muskelbeteiligung kommt es charakteristischerweise zu einer interstitiellen Lungenbeteiligung, die auch prognostisch das Krankheitsbild bestimmt. Zusätzlich können klinisch eine Polyarthritis und weitere Symptome bestehen, die dem klinischen Bild anderer Kollagenosen ähneln. Ebenso wie die Polymyositis und Dermatomyositis kann sich das Jo-1-Syndrom in sog. Myositis-Overlap-Syndromen präsentieren. Zu dieser Diagnose führt ein Symptomenkomplex, der die klare Zuordnung zu einer einzelnen Erkrankung nicht möglich macht. Häufig werden in solchen Fällen U1-RNP-Antikörper nachgewiesen. Therapeutisch spricht das Jo-1-Syndrom auf die Gabe von Kortikosteroiden und—falls notwendig—Azathioprin, Methotrexat und Cyclophosphamid an. Eine Kurzbeschreibung von zwei klinischen Fällen stellt das Krankheitsbild anschaulich dar. 相似文献